Novartis Strengthens Rare Disease Focus with $12 Billion Avidity Biosciences Deal
In a landmark move to advance treatments for rare muscle disorders, Novartis takes a major step toward expanding its innovation
Read More
Factual Version of a Story
U.S. biotech growth